Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight
The epilepsy market is expected to grow due to an increase in disease prevalence and the expected launch of emerging therapies, including Azetukalner (XEN1101; Xenon Pharmaceuticals), ABS-1230 (Actio Biosciences), BHV-7000 (Biohaven Pharmaceuticals), Relutrigine (PRAX-562; Praxis Precision Medicines), Zorevunersen (STK-001; Stoke Therapeutics), and others during the forecast period.
LAS VEGAS, Oct. 27, 2026 /PRNewswire/ -- Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Epilepsy Market Summary
Discover the future of the epilepsy diagnosis & treatment market @ https://www.delveinsight.com/report-store/epilepsy-market
Key Factors Driving the Growth of the Epilepsy Market
Shikha Bhardwaj, Associate Consultant of Forecasting & Analytics at DelveInsight, said that the epilepsy pipeline shows strong potential to address treatment gaps, focusing on Kv7 potassium channel agonists, GABAA receptor agonists, CH24H inhibitors, positive allosteric modulators of GABAA receptors, and other innovative therapies.
Epilepsy Market Analysis
Epilepsy Competitive Landscape
Some of the epilepsy drugs under development include Azetukalner (XEN1101; Xenon Pharmaceuticals), ABS-1230 (Actio Biosciences), BHV-7000 (Biohaven Pharmaceuticals), Relutrigine (PRAX-562; Praxis Precision Medicines), Zorevunersen (STK-001; Stoke Therapeutics), ETX101 (Encoded Therapeutics), Bexicaserin (LP352; Lundbeck), SPN-817 (Supernus Pharmaceuticals), NRTX-1001 (Neurona Therapeutics), NBI-'355 (Neurocrine Biosciences), and others.
Xenon Pharmaceuticals' Azetukalner (XEN1101) is a novel, potent, and selective orally administered KCNQ2/3 (Kv7.2/7.3) potassium channel opener being developed for the treatment of epilepsy, including focal onset seizures and primary generalized tonic–clonic seizures (PGTCS). As a neuronal Kv7 voltage-gated potassium channel opener, it is designed to stabilize neuronal activity, regulate action potential burst firing, and reduce neuronal hyperexcitability associated with seizures.
Actio Biosciences' ABS-1230 is an anticipated first-in-class, orally administered, selective small-molecule KCNT1 inhibitor being developed for the treatment of KCNT1-related epilepsy. In preclinical studies, ABS-1230 demonstrated inhibitory activity against all tested pathogenic KCNT1 mutations, supporting its potential to address a broad population of patients with KCNT1-related epilepsy. The therapy may also offer the convenience of oral, at-home treatment. The initial Phase Ia study is being conducted under a U.S. FDA Investigational New Drug (IND) application, with Ethics Committee approval for the study in Australia. ABS-1230 has received U.S. FDA Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug (ODD) designations.
Biohaven Pharmaceuticals' BHV-7000 is a potent and selective KCNQ2 potassium channel activator under development for epilepsy and other neurological disorders. By modulating neuronal excitability, it is designed to address the underlying mechanisms contributing to seizure activity. Currently being evaluated in Phase II/III clinical trials, BHV-7000 has demonstrated potential as a well-tolerated treatment option for patients with refractory epilepsy.
The anticipated launch of these emerging therapies are poised to transform the epilepsy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the epilepsy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the new epilepsy drugs 2026 @ Epilepsy Drugs
Recent Developments in the Epilepsy Market
Epilepsy Epidemiology Segmentation
The epilepsy epidemiology section provides insights into the historical and current epilepsy patient pool and forecasted trends for the leading markets. The US had the highest cases of epilepsy, of which nearly 67% of the cases were focal epileptic seizures, 31% were generalized epileptic seizures, while 2% of the cases were other determined or undetermined epileptic seizures.
The epilepsy treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Epilepsy Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Epilepsy Market Size in 2025
USD 10.5 Billion
Key Epilepsy Companies
Xenon Pharmaceuticals, Actio Biosciences, Biohaven Pharmaceuticals, Praxis Precision Medicines, Stoke Therapeutics, Encoded Therapeutics, Lundbeck, Supernus Pharmaceuticals, Neurona Therapeutics, Neurocrine Biosciences, Neurelis, Novartis, UCB, and others
Key Epilepsy Therapies
Azetukalner (XEN1101), ABS-1230, BHV-7000, Relutrigine (PRAX-562), Zorevunersen (STK-001), ETX101, Bexicaserin (LP352), SPN-817, NRTX-1001, NBI-'355, VALTOCO, AFINITOR DISPERZ, BRIVIACT, and others
Scope of the Epilepsy Market Report
Download the report to understand the anti-epilepsy drugs market @ Epilepsy Clinical Trials
Table of Contents
1
Epilepsy Market Key Insights
2
Epilepsy Market Report Introduction
3
Executive Summary of Epilepsy
4
Key Events of Epilepsy
5
Epilepsy Epidemiology and Market Forecast Methodology
6
Epilepsy Market Overview at a Glance
6.1
Clinical Landscape Analysis (by Phase, RoA, and Molecule Type)
6.2
Market Share (%) Distribution of Epilepsy by Therapies in 2025
6.3
Market Share (%) Distribution of Epilepsy by Therapies in 2036
7
Disease Background and Overview of Epilepsy
7.1
Introduction
7.2
Signs and Symptoms
7.3
Causes
7.4
Diagnosis
8
Treatment and Management
9
Epidemiology and Patient Population of Epilepsy in the 7MM
9.1
Key Findings
9.2
Assumptions and Rationale
9.3
Total Diagnosed Prevalent Cases of Epilepsy in the 7MM
9.4
The United States
9.4.1
Total Diagnosed Prevalent Cases of Epilepsy in the US
9.4.2
Gender-specific Diagnosed Prevalent Cases of Epilepsy in the US
9.4.3
Diagnosed Prevalent Cases of Epilepsy Based on Seizure Type in the US
9.4.4
Diagnosed Cases of Other Types of Epilepsies and Associated Diseases in the US
9.5
EU4 and the UK
9.6
Japan
10
Patient Journey of Epilepsy
11
Marketed Therapies of Epilepsy
11.1
Marketed Competitive Landscape of Epilepsy
11.2
VALTOCO: Neurelis
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Developmental Activities
11.2.4
Summary of Pivotal Trials
11.2.5
Clinical Development
11.2.5.1
Clinical Trials Information
11.2.6
Safety and Efficacy
11.2.7
Analyst Views
11.3
Everolimus (AFINITOR DISPERZ): Novartis
List to be continued in the report…
12
Emerging Therapies of Epilepsy
12.1
Emerging Competitive Landscape of Epilepsy
12.2
Azetukalner (XEN1101): Xenon Pharmaceuticals
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.3.1
Clinical Trials Information
12.2.4
Safety and Efficacy
12.2.5
Analyst Views
12.3
ABS-1230: Actio Biosciences
12.4
BHV-7000: Biohaven Pharmaceuticals
List to be continued in the report…
13
Epilepsy Market: 7MM Analysis
13.1
Key Findings
13.2
Key Epilepsy Market Forecast Assumptions
13.3
Epilepsy Market Outlook
13.4
Conjoint Analysis
13.5
Total Market Size of Epilepsy in the 7MM
13.6
Total Market Size of Epilepsy by Therapies in the 7MM
13.7
The United States Epilepsy Market Size
13.7.1
Total Market Size of Epilepsy in the United States
13.7.2
Market Size of Epilepsy by Therapies in the United States
13.8
EU4 and the UK Epilepsy Market Size
13.9
Japan Epilepsy Market Size
14
KOL Views of Epilepsy
15
SWOT Analysis of Epilepsy
16
Unmet Needs of Epilepsy
17
Market Access and Reimbursement of Epilepsy
17.1
The United States
17.2
In EU4 and the UK
17.3
Japan
17.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
17.5
Market Access and Reimbursement of Epilepsy
18
Bibliography
19
Epilepsy Market Report Methodology
Types of Epilepsy
DelveInsight possesses extensive expertise in the neurological disorders market, supported by a dedicated and experienced team specializing in this therapeutic area. The company has recently published a series of epidemiology-based market reports covering various forms of epilepsy, including Partial Epilepsy, Chronic Focal Epilepsy, Drug-Resistant Epilepsy, Dravet Syndrome, and others. These reports provide an in-depth assessment of the current treatment landscape, emerging therapies, individual treatment market shares, and historical and forecasted market sizes from 2022 to 2036 across the 7MM, comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Partial Epilepsy Market
Partial Epilepsy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key partial epilepsy companies including Vertex Pharmaceuticals, Supernus Pharmaceuticals, Xenon Pharmaceuticals, UCB Pharmaceuticals, and others.
Chronic Focal Epilepsy Market
Chronic Focal Epilepsy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic focal epilepsy companies, including GlaxoSmithKline, Sanofi, UCB Pharma, Eisai, Medtronic, and others.
Drug-Resistant Epilepsy Market
Drug-resistant Epilepsy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key drug-resistant epilepsy companies, including Neurona Therapeutics, IAMA Therapeutics, Bright Minds Bio, and others.
Dravet Syndrome Market
Dravet Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Dravet syndrome companies, including Biocodex, GW Pharmaceuticals, Zogenix, Ovid Therapeutics, PTC Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP